Preliminary safety and efficacy of TQB2930, a HER2-targeted bispecific antibody in patients with advanced breast cancer: Results from a phase 1b study

This article has no abstract
Epistemonikos ID: 77b239545df42dc127ecf50faa16e3245059d0ce
First added on: Dec 13, 2025